| Literature DB >> 15735896 |
Abstract
Allogeneic demineralized bone has been used extensively as a clinical graft material because it has osteoinductive and osteoconductive properties. Concerns over processing and terminal sterilization procedures that may reduce performance have led clinicians to call for assurances of product potency. There is extensive experience on effects of demineralized bone in animal and cell culture models with the possibility for future evidence-based standards for release of products. Evaluation of the current state of knowledge leads to the fact that we cannot conclude that performance of different lots of demineralized bone allografts in in vivo or in vitro test systems can be used as a measure of clinical performance. It may be possible to adopt an osteoinductivity standard for release-to-market, but it should be followed by clinical monitoring and further research.Mesh:
Substances:
Year: 2005 PMID: 15735896 DOI: 10.1007/s10561-005-4252-z
Source DB: PubMed Journal: Cell Tissue Bank ISSN: 1389-9333 Impact factor: 1.522